夏枯草口服液联合复方倍他米松治疗亚急性甲状腺炎的临床研究

目的探讨夏枯草口服液联合复方倍他米松治疗亚急性甲状腺炎的临床疗效。方法收集2016年1月—2017年1月在枣庄矿业集团中心医院进行诊治的亚急性甲状腺炎患者86例,根据治疗方法的差别分为对照组(43例)和治疗组(43例)。对照组患者于甲状腺肿大明显处气管旁斜放射状注射复方倍他米松注射液,每侧5 mg,第1、2周均注射2次,第3周注射1次。治疗组在对照组的基础上口服夏枯草口服液,10 m L/次,2次/d。两组患者均治疗3周。评价两组患者临床疗效,同时比较治疗前后两组患者临床症状改善情况、血清甲状腺功能和血清学指标。结果治疗后,对照组和治疗组总有效率分别为81.40%、97.67%;两组比较差异具有统计学意义(P0.05)。治疗后,治疗组退热时间、疼痛消失时间和肿块消失时间均明显短于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清游离三碘状腺素(FT3)和游离甲状腺素(FT4)水平均显著降低,促甲状腺素(TSH)水平均显著升高,同组比较差异具有统计学意义(P0.05);且治疗组血清甲状腺功能指标改善显著优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)和胰岛素样生长因子-1(IGF-1)水平均显著降低(P0.05);且治疗组血清学指标比对照组降低的更明显(P0.05)。结论夏枯草口服液联合地塞米松治疗亚急性甲状腺炎可有效改善患者临床症状和甲状腺功能,并可降低机体炎症反应,具有一定的临床推广应用价值。

Clinical study on Xiakucao Oral Liquid combined with compound betamethasone in treatment of subacute thyroiditis

Objective To investigate the clinical efficacy of Xiakucao Oral Liquid combined with compound betamethasone in treatment of subacute thyroiditis.Methods Patients (86 cases) with subacute thyroiditis in Zaozhuang Mining Group Central Hospital from January 2016 to January 2017 were divided into control (43 cases) and treatment (43 cases) groups based on different treatments. Patients in the control group wereadministered with Compound Betamethasone Injection by radial injection at the location of oblique trachea of obvious thyroid swollen, 5 mg each side, twice a week at the first and second weeks, then once at the third week. Patients in the treatment group werepo administered with Xiakucao Oral Liquid on the basis of the control group, 10 mL/time, twice daily. Patients in two groups were treated for 3 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of clinical symptom, serum thyroid function, and serological markers in two groups before and after treatment was compared.Results After treatment, the clinical efficacy in the control and treatment groups were 81.40％ and 97.67％, respectively, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of fever, pain and lump in treatment group were significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the FT3 and FT4 levels in two groups were significantly decreased, but TSH was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the serum thyroid function in the treatment group was significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the CRP, TNF-α and IGF-1 levels in two groups were significantly decreased (P < 0.05). And the serological markers in the treatment group were significantly lower than those in the control group (P < 0.05).Conclusion Xiakucao Oral Liquid combined with compound betamethasone can effectively improve the clinical symptoms and thyroid function in treatment of subacute thyroiditis, and can reduce inflammatory response, which has a certain clinical application value.